IRVINE, California, December 21, 2007 - Teva Health Systems is pleased to announce the introduction and availability of Ceftriaxone for Injection, USP. This product is AP rated to Rocephin®* for Injection. Ceftriaxone for Injection is available in 250 mg/vial, 500 mg/vial, 1 gm/vial, and 2 gm/vial, in single dose glass vials, and 10 gm/vial in multiple dose glass vials. “Teva Health Systems is committed to providing high-quality, cost-effective pharmaceuticals to our customers and patients,” states Jonathan Zalk, Marketing Director. “We are excited to offer Ceftriaxone for Injection to meet their needs.”
Teva Health Systems is a part of Teva Pharmaceuticals, the leading pharmaceutical manufacturer for both new and total prescriptions.‡ The company has an aggressive Research and Development effort and one of the best overall ANDA approval records in the industry.‡
No comments:
Post a Comment